NLS Pharmaceutics AG: NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Statistically significant results with Quilience® (Mazindol ER) achieving a 7.1 point mean reduction in ESS from baseline compared to a 3.2 point reduction for placebo, p=0.0081Fast onset of action from
Source: finanznachrichten.de